Home » Healthcare » Pharmaceuticals » Chronic Idiopathic Constipation (CIC) Drugs Market

Global Chronic Idiopathic Constipation (CIC) Drugs Market By Drug Type (Lubiprostone, Linaclotide, Pipeline Drug Analysis: Phase 3: Plecanatide, Elobixibat, Others), Prescription Type (Prescribed, Over the Counter Drugs) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2030

Published: | Report ID: 7446 | Report Format : PDF

Key Highlights of the Report

How are the major segments performing in the Chronic Idiopathic Constipation (CIC) Drugs market?

  • In 2022, the lubiprostone segment accounted for the largest market share as it is more efficacious than a placebo in treating chronic idiopathic constipation.
  • In 2022, the hospitals & clinics segment was anticipated to hold a prominent share in the global chronic idiopathic constipation (CIC) drugs market. This is mainly due to the increasing healthcare spending.

What is the Market Size of Chronic Idiopathic Constipation (CIC) Drugs regarding value?

The global chronic idiopathic constipation (CIC) drugs market is anticipated to grow at a substantial CAGR of 7.10% in the upcoming years. The global Chronic Idiopathic Constipation (CIC) Drugs industry was estimated to be worth USD 4,846.5 million in 2022 and was expected to be worth USD 7,833.5 million by 2030.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Which region dominated the Chronic Idiopathic Constipation (CIC) Drugs market?

In 2022, the North American region was anticipated to hold a prominent share of the global chronic idiopathic constipation (CIC) drugs market. As a result of the presence of numerous manufacturers of constipation medications, the United States holds the largest market share in North America. Furthermore, several market players are involved in product launches, contributing to the region’s growth. About 16 out of 100 people suffer from constipation. The growing incidence rate of constipation among people ages 60 and above is expected to fuel the target market’s growth over the study period by increasing the demand for effective treatment.

How US Market is Performing in the Chronic Idiopathic Constipation (CIC) Drugs Market?

In North America, the United States holds the largest market share because of factors such as numerous manufacturers of constipation medications. In addition, several market players are involved in product launches, contributing to the region’s growth. Since lifestyle-related diseases, constipation, higher healthcare spending, and greater adoption of pharmaceuticals to treat ailments are among the factors contributing to the largest market for CIC drugs, the US is the world’s largest market for CIC drugs. In the US, CIC affects approximately 63 million people, according to the National Institutes of Health (NIH).

How does the economy impact global Chronic Idiopathic Constipation (CIC) Drugs growth?

It is estimated that the COVID-19 pandemic will moderately impact the global chronic idiopathic constipation treatment market in 2020. The demand for chronic idiopathic constipation treatment is expected to rise in the first quarter of 2020 steadily. Due to the outbreak of COVID-19 at the end of the first quarter of 2020, governments are expected to impose stringent lockdown measures in the second and third quarters of 2020, negatively impacting the adoption of chronic idiopathic constipation treatments. However, as governments gradually lift lockdown measures, the demand for chronic idiopathic constipation will grow substantially by the end of 2020.

What is the competitive environment of the Chronic Idiopathic Constipation (CIC) Drugs market?

The chronic idiopathic constipation (CIC) drugs industry’s competitive environment provides information on the entire economic profit made by suppliers and businesses, the sales and revenues created in this sector, the chronic idiopathic constipation (CIC) drugs market share globally, the business organization summary, the introduction of new products, and the opportunities for the industrial chronic idiopathic constipation (CIC) drugs market. For instance, in April 2020, the USPTO granted an application for patent protection covering the formulation of the 72-mcg dose of LINZESS (United States Patent and Trademark Office).

Executive Summary

What are the key trends in the Chronic Idiopathic Constipation (CIC) Drugs market?

Globally, constipation prevalence is rising, leading to high demand for newer therapeutics, which will drive the market. Currently, available chronic idiopathic constipation treatment options do not meet the needs of patients or providers. The unpredictability of nonprescription laxatives, bloating, poor symptom relief, or inability to improve quality of life makes around 50% of patients with chronic idiopathic constipation dissatisfied. In order to address these concerns, novel agents with novel mechanisms of action have been developed for the past ten years. Several of the available specialty drugs are also aimed at adolescents and adults. Developing and launching pediatric constipation drugs will likely be a significant opportunity for key players and new entrants as the incidence of constipation among children increases.

How are Food Manufacturers Teaming Up with Stakeholders in Chronic Idiopathic Constipation (CIC) Drugs Market?

There are few market players in chronic idiopathic constipation, which creates plenty of opportunities for new entrants. Additionally, Mallinckrodt plc announced in February that it was acquiring Sucampo Pharmaceuticals, Inc., a biopharmaceutical company. In addition to the FDA-approved blockbuster drug Amitiza (lubiprostone), the company acquired other assets, including irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). In addition to Par Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories Ltd, Sucampo Pharmaceuticals, Inc. has partnered with both companies to market lubiprostone in the United States beginning in January 2021 under a non-exclusive license agreement. This type of inorganic strategy by market players is expected to boost market growth significantly in the next few years. From Albireo AB, a Swedish biotechnology company, Ferring Pharmaceuticals acquired the rights to develop and commercialize Elobixibat, a first-of-its-kind compound for chronic idiopathic constipation.

Which are the key investments by the Chronic Idiopathic Constipation (CIC) Drugs market players?

Leading players operating in the chronic idiopathic constipation (CIC) drugs market are focusing on expansion in production capacities for chronic idiopathic constipation (CIC) drugs. In addition, in order to acquire a competitive edge, competitors are focusing on strategic mergers and acquisitions, partnerships, and raising manufacturer awareness through a variety of associations established to encourage smart practises to service more end users in the domestic market. For instance, in September 2019, AstraZeneca and Ironwood Pharmaceuticals, Inc. amended their collaboration agreement to develop and commercialize LINZESS in China.

Some major players in the chronic idiopathic constipation (CIC) drugs market are Actavis, Synergy Pharmaceuticals, Chugai Pharmaceutical, Roche Holding, Ferring International Center, Pfizer, GlaxoSmithKline, Sanofi, Bayer, Sucampo Pharmaceuticals, Salix Pharmaceuticals, Ironwood Pharmaceuticals, Progenics Pharmaceuticals.

Chronic Idiopathic Constipation (CIC) Drugs Market

What are the Major Driving Factors for the Chronic Idiopathic Constipation (CIC) Drugs Market?

During the forecast period, the market is expected to grow due to increased clinical trials and approvals of drug candidates to address unmet medical needs for chronic idiopathic constipation treatment. For example, Shire plc received a new drug application from the U.S. FDA for the indication of chronic idiopathic constipation in adults in March 2018. Furthermore, SHP555 (prucalopride) was approved by the European Commission in 2015 as a symptomatic treatment for chronic constipation in adults failing to respond to laxatives. To treat multiple gastrointestinal disorders, including chronic idiopathic constipation, Renexxion conducts a phase 2 clinical trial of Naronapride (ATI-7505).

What are the Major Risks for the Chronic Idiopathic Constipation (CIC) Drugs Market?

The costs of chronic idiopathic constipation are significant. They are similar to other common conditions associated with greater morbidity and healthcare expenditures. According to the American Journal of Managed Care, 81% of chronic idiopathic constipation treatment costs are incurred due to medical services, including physician visits and outpatient treatment. A study reveals that patients with abdominal symptoms suffering from chronic constipation experience 16 times higher pharmacy costs than those without abdominal symptoms. The cost of treatment is an important factor to consider when choosing a treatment. As a result, the market is hindered by higher costs associated with treatment.

Which is the key application in the Chronic Idiopathic Constipation (CIC) Drugs market?

The hospitals & clinics segment is expected to hold a prominent share of the global chronic idiopathic constipation (CIC) drugs market during the forecast period. As a result of an increase in the number of chronic idiopathic constipation patients, the adoption of newer products will increase. Since patients are becoming more informed and proactive regarding their health, they will likely seek effective treatment, boosting healthcare spending on constipation. Chronic idiopathic constipation significantly impacts the healthcare system, according to an article in the American Journal of Managed Care in 2007.

How is the Chronic Idiopathic Constipation (CIC) Drugs market performing in regions?

Asia Pacific market is anticipated to witness the fastest growth in the global chronic idiopathic constipation (CIC) drugs market during the forecast period. The rising demand for diagnostic tests and the growing attention on early diagnosis and treatment of GI diseases will also drive the growth of the region’s chronic idiopathic constipation treatment market over the next few years.

What is the regulatory landscape for the Chronic Idiopathic Constipation (CIC) Drugs market?

Global market growth is largely driven by the increasing number of clinical trials and drug approvals introduced by pharmaceutical companies to address unmet medical needs for CIC treatment. For chronic idiopathic constipation, very few approved treatments are available. According to Shire plc, it received an award from the U.S. Food and Drug Administration in March 2018 for its drug candidate, SHP555 (prucalopride), which the agency has approved for treating chronic idiopathic constipation in adults.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

What are the major players planning for the future of the Chronic Idiopathic Constipation (CIC) Drugs market?

A competitive edge in the market is predicted to be provided by growing regional presence and investments in downstream applications. For instance, in February 2018, Amitiza, Sucampo’s leading global branded constipation product, was acquired by Mallinckrodt Sucampo’s primary product was Amitiza

REPORT ATTRIBUTE DETAILS
Chronic Idiopathic Constipation (CIC) Drugs Market by Value Yes
Chronic Idiopathic Constipation (CIC) Drugs Market, Tornado Analysis Yes
Chronic Idiopathic Constipation (CIC) Drugs Market, STAR Analysis Yes
Chronic Idiopathic Constipation (CIC) Drugs Market, SRC Analysis Yes
Chronic Idiopathic Constipation (CIC) Drugs Market Pricing Analysis Yes (On Demand)
Chronic Idiopathic Constipation (CIC) Drugs Market Segment Analysis By Type (Lubiprostone, Linaclotide, and Others)

By Application (Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, and Others

Chronic Idiopathic Constipation (CIC) Drugs Market, Regional Analysis North America (US and Canada)

Europe (Germany, UK, France, Italy, Spain, and the Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, South East Asia, and the Rest of Asia Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East and Africa (GCC Countries, South Africa, and the Rest of Middle East and Africa)

Chronic Idiopathic Constipation (CIC) Drugs Market Key Companies Actavis, Synergy Pharmaceuticals, Chugai Pharmaceutical, Roche Holding, Ferring International Center, Pfizer, GlaxoSmithKline, Sanofi, Bayer, Salix Pharmaceuticals, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Progenics Pharmaceuticals
Chronic Idiopathic Constipation (CIC) Drugs Market Competitive Landscape Market Share Analysis

Competitive Benchmarking

Key Players Market Positioning

Geographical Presence Analysis

Major Strategies Adopted

Segmentation of Global Chronic Idiopathic Constipation (CIC) Drugs Market-

Global Chronic Idiopathic Constipation (CIC) Drugs Market – By Type

  • Lubiprostone
  • Linaclotide
  • Others

Global Chronic Idiopathic Constipation (CIC) Drugs Market – By Application

  • Hospitals & Clinics
  • Ambulatory Surgical Centres
  • Long Term Care Centres
  • Others

Global Chronic Idiopathic Constipation (CIC) Drugs Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Chronic Idiopathic Constipation (CIC) Drugs Market
2.2. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Type
2.3. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Application
2.4. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Chronic Idiopathic Constipation (CIC) Drugs Market Value, 2017-2030, (US$ Mn))
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type
3.5.2. Application
3.5.3. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Type Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Application Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Chronic Idiopathic Constipation (CIC) Drugs Market
7.1. Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
7.1.1. Overview
7.1.2. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Type, 2022 vs 2030 (in%)
7.1.3. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Lubiprostone, 2017-2030 (US$ Mn))
7.1.4. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Linaclotide, 2017-2030 (US$ Mn))
7.1.5. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Others, 2017-2030 (US$ Mn))
7.2. Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
7.2.1. Overview
7.2.2. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Application, 2022 vs 2030 (in%)
7.2.3. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Hospitals & Clinics, 2017-2030 (US$ Mn))
7.2.4. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Ambulatory Surgical Centres, 2017-2030 (US$ Mn))
7.2.5. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Long Term Care Centres, 2017-2030 (US$ Mn))
7.2.6. Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Others, 2017-2030 (US$ Mn))

8. North America Chronic Idiopathic Constipation (CIC) Drugs Market Analysis
8.1. North America Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030(US$ Mn))
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030(US$ Mn))
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
8.3.1. U.S.
8.3.1.1. U.S. Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
8.3.1.2. U.S. Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
8.3.1.3. U.S. Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
8.3.2. Canada
8.3.2.1. Canada Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
8.3.2.2. Canada Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
8.3.2.3. Canada Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))

9. Europe Chronic Idiopathic Constipation (CIC) Drugs Market Analysis
9.1. Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030(US$ Mn))
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030(US$ Mn))
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
9.3.1. Germany
9.3.1.1. Germany Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.3.1.2. Germany Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
9.3.1.3. Germany Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
9.3.2. France
9.3.2.1. France Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.3.2.2. France Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
9.3.2.3. France Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
9.3.3. UK
9.3.3.1. UK Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.3.3.2. UK Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
9.3.3.3. UK Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
9.3.4. Italy
9.3.4.1. Italy Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.3.4.2. Italy Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
9.3.4.3. Italy Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
9.3.5. Spain
9.3.5.1. Spain Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.3.5.2. Spain Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
9.3.5.3. Spain Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
9.3.6. Rest of Europe
9.3.6.1. Rest of Europe Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
9.3.6.2. Rest of Europe Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
9.3.6.3. Rest of Europe Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))

10. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Analysis
10.1. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030(US$ Mn))
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030(US$ Mn))
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
10.3.1. China
10.3.1.1. China Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.3.1.2. China Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
10.3.1.3. China Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
10.3.2. Japan
10.3.2.1. Japan Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.3.2.2. Japan Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
10.3.2.3. Japan Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
10.3.3. India
10.3.3.1. India Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.3.3.2. India Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
10.3.3.3. India Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
10.3.4. South Korea
10.3.4.1. South Korea Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.3.4.2. South Korea Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
10.3.4.3. South Korea Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
10.3.5. South-East Asia
10.3.5.1. South-East Asia Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.3.5.2. South-East Asia Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
10.3.5.3. South-East Asia Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
10.3.6. Rest of Asia Pacific
10.3.6.1. Rest of Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
10.3.6.2. Rest of Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
10.3.6.3. Rest of Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))

11. Latin America Chronic Idiopathic Constipation (CIC) Drugs Market Analysis
11.1. Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030(US$ Mn))
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030(US$ Mn))
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
11.3.1. Brazil
11.3.1.1. Brazil Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.3.1.2. Brazil Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
11.3.1.3. Brazil Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
11.3.2. Mexico
11.3.2.1. Mexico Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.3.2.2. Mexico Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
11.3.2.3. Mexico Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
11.3.3. Rest of Latin America
11.3.3.1. Rest of Latin America Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
11.3.3.2. Rest of Latin America Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
11.3.3.3. Rest of Latin America Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))

12. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market Analysis
12.1. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030(US$ Mn))
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030(US$ Mn))
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
12.3.1. GCC Countries
12.3.1.1. GCC Countries Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.3.1.2. GCC Countries Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
12.3.1.3. GCC Countries Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
12.3.2. South Africa
12.3.2.1. South Africa Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.3.2.2. South Africa Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
12.3.2.3. South Africa Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))
12.3.3. Rest of Middle East and Africa
12.3.3.1. Rest of Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market Estimates and Forecast, 2017-2030 (US$ Mn))
12.3.3.2. Rest of Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs, By Type, 2017-2030 (US$ Mn))
12.3.3.3. Rest of Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs, By Application, 2017-2030 (US$ Mn))

13. Company Profiles
13.1. Actavis
13.1.1. Company Overview
13.1.2. Applications/Types Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2022)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Chugai Pharmaceutical
13.3. Ferring International Center
13.4. Synergy Pharmaceuticals
13.5. Pfizer
13.6. GlaxoSmithKline
13.7. Roche Holding
13.8. Sanofi
13.9. Bayer
13.10. Salix Pharmaceuticals
13.11. Sucampo Pharmaceuticals
13.12. Ironwood Pharmaceuticals
13.13. Progenics Pharmaceuticals

List of Figures
FIG. 1 Global Chronic Idiopathic Constipation (CIC) Drugs Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Chronic Idiopathic Constipation (CIC) Drugs Market Segmentation
FIG. 4 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2022 (US$ Mn))
FIG. 5 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2022 (US$ Mn))
FIG. 6 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Geography, 2022 (US$ Mn))
FIG. 7 Attractive Investment Proposition, by Type, 2022
FIG. 8 Attractive Investment Proposition, by Application, 2022
FIG. 9 Attractive Investment Proposition, by Geography, 2022
FIG. 10 Global Market Share Analysis of Key Chronic Idiopathic Constipation (CIC) Drugs Market Manufacturers, 2022
FIG. 11 Global Market Positioning of Key Chronic Idiopathic Constipation (CIC) Drugs Market Manufacturers, 2022
FIG. 12 Global Chronic Idiopathic Constipation (CIC) Drugs Market Value Contribution, By Type, 2022 & 2030 (Value %)
FIG. 13 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Lubiprostone, Value, 2017-2030 (US$ Mn))
FIG. 14 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Linaclotide, Value, 2017-2030 (US$ Mn))
FIG. 15 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Others, Value, 2017-2030 (US$ Mn))
FIG. 16 Global Chronic Idiopathic Constipation (CIC) Drugs Market Value Contribution, By Application, 2022 & 2030 (Value %)
FIG. 17 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Hospitals & Clinics, Value, 2017-2030 (US$ Mn))
FIG. 18 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Ambulatory Surgical Centres, 2017-2030 (US$ Mn))
FIG. 19 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Long Term Care Centres, 2017-2030 (US$ Mn))
FIG. 20 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Others, 2017-2030 (US$ Mn))
FIG. 21 North America Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 22 U.S. Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 23 Canada Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 24 Europe Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 25 Germany Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 26 France Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 27 U.K. Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 28 Italy Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 29 Spain Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 30 Rest of Europe Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 31 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 32 China Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 33 Japan Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 34 India Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 35 South Korea Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 36 South-East Asia Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 37 Rest of Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 38 Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 39 Brazil Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 40 Mexico Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 41 Rest of Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 42 Middle East & Africa Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 43 GCC Countries Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 44 South Africa Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))
FIG. 45 Rest of Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, 2017-2030 (US$ Mn))

List of Tables
TABLE 1 Market Snapshot: Global Chronic Idiopathic Constipation (CIC) Drugs Market
TABLE 2 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Competitive Benchmarking, 2022
TABLE 3 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Geographical Presence Analysis, 2022
TABLE 4 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Key Strategies Analysis, 2022
TABLE 5 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 6 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 7 Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Geography, 2017-2030 (US$ Mn))
TABLE 8 North America Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 9 North America Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 10 North America Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
TABLE 11 US Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 12 US Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 13 Canada Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 14 Canada Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 15 Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 16 Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 17 Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
TABLE 18 Germany Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 19 Germany Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 20 France Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 21 France Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 22 UK Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 23 UK Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 24 Italy Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 25 Italy Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 26 Spain Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 27 Spain Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 28 Rest of Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 29 Rest of Europe Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 30 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 31 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 32 Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
TABLE 33 China Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 34 China Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 35 Japan Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 36 Japan Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 37 India Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 38 India Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 39 South Korea Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 40 South Korea Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 41 South-East Asia Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 42 South-East Asia Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 43 Rest of Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 44 Rest of Asia Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 45 Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 46 Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 47 Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
TABLE 48 Brazil Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 49 Brazil Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 50 Mexico Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 51 Mexico Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 52 Rest of Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 53 Rest of Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 54 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 55 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 56 Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Country, 2017-2030 (US$ Mn))
TABLE 57 GCC Countries Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 58 GCC Countries Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 59 South Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 60 South Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))
TABLE 61 Rest of Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2030 (US$ Mn))
TABLE 62 Rest of Middle East and Africa Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2030 (US$ Mn))

Frequently Asked Questions

How does COVID-19 Impact the global Chronic Idiopathic Constipation (CIC) Drugs market?

It is estimated that the COVID-19 pandemic will moderately impact the global chronic idiopathic constipation treatment market in 2020. The demand for chronic idiopathic constipation treatment is expected to rise in the first quarter of 2020 steadily.

Which is the leading region of the market for Chronic Idiopathic Constipation (CIC) Drugs?

North America accounted for the most heightened share in the global chronic idiopathic constipation (CIC) drugs market.

What are the key drivers for the growth of the Chronic Idiopathic Constipation (CIC) Drugs market?

The growing aging population is expected to boost the growth of the chronic idiopathic constipation treatment market during the forecast period.

Which is the major segment in the Chronic Idiopathic Constipation (CIC) Drugs market by type?

The lubiprostone segment had a major share in the global market in 2022.

Which is the major segment in the Chronic Idiopathic Constipation (CIC) Drugs market by application?

Actavis Product Portfolio, Strategic MovesSCOT Analysis, Chugai Pharmaceutical, Chugai Pharmaceuticals Products Portfolio, Strategic Moves, SCOT Analysis are some of the major players in the global market.

OTC Vitamins Dietary Supplements Market

Published:
Report ID: 35994

US Retail Pharmacy Market

Published:
Report ID: 32801

Liposomes Market

Published:
Report ID: 35888

UK Iron Supplement Market

Published:
Report ID: 35709

U.S. Iron Supplement Market

Published:
Report ID: 35688

Malignant Ascites Market

Published:
Report ID: 11184

Middle East and Africa In-Vitro Fertilization (IVF) Market

Published:
Report ID: 35578

Chronic Myeloid Leukemia (CML) Treatment Market

Published:
Report ID: 2939

Combination Therapies In Aesthetics Market

Published:
Report ID: 35434

CAR T-Cell Therapy Market

Published:
Report ID: 2051

OTC Cough Cold And Allergy Medicine Market

Published:
Report ID: 20062

Heart Health Supplements Market

Published:
Report ID: 6184

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN